China's biotech pipeline is brimming with PD-1/L1 checkpoints. Are they really needed?
The big US and European markets aren’t the only place where PD-1/L1 checkpoint drugs are crowding in. Beginning later this year, the data analytics firm PharmCube reports, Keytruda and Opdivo should both be green lighted for marketing in China. And they’ll likely be swiftly followed by 4 Chinese biopharmas angling for their own share of the market — with a dozen more behind them preparing to make an impact on China and the world.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
